Business
BioVersys and Hackensack Meridian Health partner on novel ansamycin molecules for non-tuberculous mycobacteria
Novel ansamycin small molecules developed at Hackensack Meridian Health's Center for Discovery and Innovation are moving into joint profiling and...
Galapagos agrees with Gilead to take on Ouro Medicines' gamgertamig T cell engager
Gamgertamig, a BCMAxCD3 bispecific T cell engager developed by Ouro Medicines, sits at the center of a three-way collaboration agreement announced March 31...
Ambrosia Bio closes USD 100 million Series B to advance GLP-1 cardiometabolic pipeline
Boulder, Colorado-based Ambrosia Biosciences Inc. has closed an oversubscribed USD 100 million Series B financing round to advance its oral small molecule...
Biogen moves on Apellis Pharma for USD 5.6b to strengthen complement immunology portfolio
Biogen Acquires Apellis Pharmaceuticals to Consolidate Complement Immunology Portfolio in USD 5.6 Billion Deal
Eli Lilly expands from neuroscience to sleep medicine via USD 7.8b Centessa acquisition
Eli Lilly Expands Neuroscience Portfolio into Sleep Medicine via USD 7.8 Billion Acquisition of Centessa Pharmaceuticals
Aurinia expands autoimmune portfolio via Kezar acquisition
Aurinia Pharmaceuticals Expands Autoimmune Portfolio via $6.955/Share Acquisition of Kezar Life Sciences
Memo Therapeutics and CSL Partner on $328M Recombinant IgG Technology Collaboration
Memo Therapeutics and CSL Forge Strategic Collaboration in Recombinant Polyclonal IgG Technology
Dianthus Therapeutics raises USD 625m in upsized underwritten public offering
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company based in New York City and Waltham, Massachusetts, announced the pricing...
Crossbow Therapeutics Raises USD 77 Million in Series B to Advance Cancer Therapies
Crossbow Therapeutics, a Cambridge, Massachusetts-based biotechnology company developing TCR-mimetic antibody therapies for oncology, has closed a Series B...
ApoE4.Info and ApoE4 Alzheimer's Alliance partner on precision advocacy for APOE4 carriers
ApoE4.Info and the ApoE4 Alzheimer's Alliance, two Washington-based nonprofit organizations, announced an ApoE4 partnership on March 16, 2026, to coordinate...
Vanda Pharmaceuticals' imsidolimab BLA accepted by FDA for generalized pustular psoriasis treatment
Washington, D.C.-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced on February 25, 2026, that the US FDA has accepted its Biologics License...
Teva Pharmaceutical Secures USD 400 Million Strategic Growth Capital From Blackstone Life Sciences
Teva Pharmaceutical Industries, the Israel-headquartered pharmaceutical company with U.S. operations based in Parsippany, New Jersey, has entered into a USD...
Ten63 Therapeutics Closes Strategic Financing Round Bringing Total Funding Past USD 45 Million
Ten63 Therapeutics, a Durham, North Carolina–based AI drug discovery company developing small molecules against targets long considered undruggable, has...
Atrium Therapeutics Launches With USD 270 Million as Avidity Biosciences Spinoff Targeting Cardiac RNA Medicines
San Diego-based Atrium Therapeutics has debuted as a publicly traded company (Nasdaq: RNA) with approximately USD 270 million in cash and cash equivalents...
R1 Therapeutics Launches With Oversubscribed $77.5 Million Series A for Kidney Disease Therapies
R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A...
The AllSci Brief
Systematic R&D and deal news. Daily.